Roche Aktie

272,20 EUR +7,80 EUR +2,95 %

14.04.2025

L&S

251,89 CHF +9,18 CHF +3,78 %

14.04.2025

BRX

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.209,42 Mrd. EUR

KGV24,60Div. Rendite3,80%

WKN855167

ISINCH0012032048

SymbolRHHVF

Roche Aktien News

Sortieren:Datum Meistgelesen

17.07.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

17.07.24Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

10.07.24PR NewswireRemix Therapeutics™ Attains Near-Term Milestone from Roche Collaboration

09.07.24GlobeNewswireRoche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

09.07.24Roche Holding AGRoche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes

08.07.24GlobeNewswireRoche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

08.07.24Roche Holding AGRoche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)

05.07.24GlobeNewswireFDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss

05.07.24Roche Holding AGFDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss

04.07.24GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

04.07.24Roche Holding AG[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer

28.06.24GlobeNewswireRoche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)

28.06.24Roche Holding AGRoche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)

28.06.24GlobeNewswireCHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition

28.06.24Roche Holding AGCHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition

27.06.24GlobeNewswireRoche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection

27.06.24Roche Holding AGRoche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection

25.06.24GlobeNewswireRoche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

25.06.24Roche Holding AGRoche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

24.06.24GlobeNewswireRoche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories

24.06.24Roche Holding AGRoche launches new analytical units for cobas® pro integrated solutions delivering greater efficiency and capacity to laboratories

20.06.24GlobeNewswireRoche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

20.06.24Roche Holding AGRoche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma

18.06.24PR NewswireRoche receives FDA clearance on its digital pathology solution for diagnostic use

15.06.24GlobeNewswireRoche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

15.06.24Roche Holding AGRoche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

10.06.24GlobeNewswireRoche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

10.06.24Roche Holding AGRoche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization

10.06.24GlobeNewswireEuropean Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

10.06.24Roche Holding AGEuropean Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer

07.06.24GlobeNewswireFive-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

07.06.24Roche Holding AGFive-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

29.05.24GlobeNewswireFDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

29.05.24Roche Holding AGFDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

27.05.24Roche Holding AGChanges to the Roche Enlarged Corporate Executive Committee

27.05.24GlobeNewswireWechsel in der erweiterten Konzernleitung von Roche

27.05.24GlobeNewswireChanges to the Roche Enlarged Corporate Executive Committee

27.05.24PR NewswireRoche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing

22.05.24Roche Holding AGRoche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) - a key marker for hereditary cardiovascular risk

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.